36622-24-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-(-)-Verapamilic Acid is used as a precursor for the synthesis of Verapamil, a calcium antagonist, for the treatment of various cardiovascular conditions such as hypertension, angina, and arrhythmias. Its role in the production of Verapamil highlights its importance in the development of medications that help manage and treat these health issues.
Used in Research and Development:
(S)-(-)-Verapamilic Acid is also utilized in research and development for the study of its chemical properties, enantiomeric behavior, and potential applications in the creation of new drugs with improved efficacy and reduced side effects. This contributes to the advancement of pharmaceutical science and the development of innovative treatments for various medical conditions.

Upstream product

• 102201-30-9 4-(3 4-dimethoxyphenyl)-4-cyano-5-methylcapronitrile 
• 20850-49-1 2-(3,4-dimethoxyphenyl)-3-methylbutyronitrile 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 36622-23-8 4-cyano-4-(3,4-dimethoxyphenyl)-5-methyl hexanoic acid 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 36770-70-4 2-(3,4-dimethoxyphenyl)-5-hydroxy-2-(methylethyl)pentanenitrile 

Downstream Products

• 204642-98-8 (S)-verapamilamide 
• 204642-98-8 (R)-verapamilamide 
• 36622-28-3 (-)-Verapamil hydrochloride 
• 152-11-4 (+)-Verapamil hydrochloride 
• 36622-24-9 (S)-verapamilic acid 
• 36622-24-9 (R)-verapamilic acid 
• 204642-98-8 verapamilamide 

Relevant academic research and scientific papers

Design, synthesis, and preliminary pharmacological evaluation of 4-aminopiperidine derivatives as N-type calcium channel blockers active on pain and neuropathic pain

Several compounds with a 4-aminopiperidine scaffold decorated on both nitrogen atoms by alkyl or acyl moieties containing the structural motifs of verapamil and of flunarizine, as well as those that are more frequent in known N-type calcium channel antago

A scaleable route to the pure enantiomers of verapamil

A versatile route to single enantiomer verapamil from readily available raw materials is described. The key intermediate, 4-cyano-4-(3,4-dimethoxyphenyl)-5-methyl hexanoic acid (verapamilic acid), was resolved efficiently with α-methyl benzylamine. Stereochemical integrity at the quaternary carbon centre was preserved through subsequent steps to give either (R)-or (S)-verapamil in good overall yield. This sequence incorporated a selective borane-mediated reduction of a tertiary amide. Process scale-up to the pilot plant has been demonstrated successfully for the resolution step.